Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 6/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26614874 | 1.00 | KCNH2 (0.35) | KCNH2SLC6A2SLC6A4EEDRBBP4 | |
| SCHEMBL32677061 | 1.00 | KCNH2 (0.35) | KCNH2SLC6A2SLC6A4EEDRBBP4 | |
| SCHEMBL32677241 | 1.00 | KCNH2 (0.35) | KCNH2SLC6A2SLC6A4EEDRBBP4 | |
| SCHEMBL26614850 | 1.00 | KCNH2 (0.35) | KCNH2SLC6A2SLC6A4EEDRBBP4 | |
| SCHEMBL32677243 | 1.00 | KCNH2 (0.35) | KCNH2SLC6A2SLC6A4EEDRBBP4 | |
| SCHEMBL2113683 | 0.77 | SSTR4 (0.33) | KCNH2HTR2ASSTR4 | |
| SCHEMBL2113685 | 0.77 | SSTR4 (0.33) | KCNH2HTR2ASSTR4 | |
| SCHEMBL2113687 | 0.77 | SSTR4 (0.33) | KCNH2HTR2ASSTR4 | |
| SCHEMBL27209301 | 0.77 | SSTR4 (0.33) | KCNH2HTR2ASSTR4 | |
| Hydrochloric Acid SCHEMBL30380230 | 0.75 | SSTR4 (0.33) | HTR2ASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4688782-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024222842-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, CBR1, SRD5A1 | KCNH2 2519/4885SLC6A2 278/4885SLC6A4 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.